Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives $33.67 Average Price Target from Analysts

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has earned a consensus recommendation of “Buy” from the eleven analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $35.6667.

A number of research analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. Barclays initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price target for the company. Truist Financial lifted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday. Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, December 22nd. Finally, Bank of America raised their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 12,300 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the sale, the chief accounting officer directly owned 5,650 shares in the company, valued at $170,630. The trade was a 68.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Mark Sabag sold 216,892 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total value of $6,231,307.16. Following the transaction, the insider directly owned 52,828 shares in the company, valued at $1,517,748.44. This represents a 80.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 622,060 shares of company stock valued at $17,076,965. Corporate insiders own 0.49% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Grove Bank & Trust raised its position in shares of Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares during the period. Advisors Asset Management Inc. bought a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $41,000. Cromwell Holdings LLC grew its stake in Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after buying an additional 629 shares in the last quarter. Sound Income Strategies LLC grew its stake in Teva Pharmaceutical Industries by 3,715.8% in the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after buying an additional 2,824 shares in the last quarter. Finally, MAI Capital Management raised its holdings in Teva Pharmaceutical Industries by 26.8% during the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after acquiring an additional 697 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 results materially beat expectations — EPS $0.96 vs. $0.65 consensus and revenue $4.71B vs. $4.36B; management highlighted branded-drug strength (notably Austedo) and a Sanofi milestone that lifted the quarter. TEVA’s Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
• Positive Sentiment: Fourth-quarter profit/revenue rise story notes the milestone payment that kicked off a late‑stage IBD study and helped drive results — supports the case for durable branded-product growth. Teva Pharmaceutical profit, revenue rise in fourth quarter
• Positive Sentiment: Analysts raised targets: Truist bumped its target to $38 (buy) and Scotiabank to $40 (sector outperform), signaling dealer confidence in upside from the beat and pipeline progress. Benzinga TickerReport — Scotiabank target raise
• Positive Sentiment: Company highlights 3rd consecutive year of growth (2025 revenues $17.3B) and positions its pipeline as value‑creating, which supports a longer‑term growth narrative beyond near‑term guidance. GlobeNewswire — Teva delivers 3 consecutive years of growth
• Neutral Sentiment: Company released the earnings slide deck and hosted an earnings call — useful for investors wanting details on segment trends, pipeline timelines and margin assumptions. MarketBeat — Earnings materials
• Neutral Sentiment: Seeking Alpha published the Q4 earnings call transcript and the results presentation for investors who want full management commentary and Q&A. SA — Earnings call transcript SA — Presentation
• Neutral Sentiment: PR/awareness activity (Will Forte campaign about Huntington’s disease) may raise public awareness but is unlikely to move near‑term fundamentals materially. Yahoo Finance — Will Forte Teams Up with Teva
• Negative Sentiment: FY‑2026 guidance is cautious on revenue: EPS guidance of 2.57–2.77 is roughly in line with consensus, but the revenue range of $16.4–16.8B sits below the ~$17.0B street estimate — investors may view this as a near‑term headwind despite the quarter’s beat.

Teva Pharmaceutical Industries Trading Down 0.5%

NYSE:TEVA opened at $33.04 on Friday. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $33.44. The firm has a 50-day moving average price of $30.29 and a two-hundred day moving average price of $23.03. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. The firm has a market cap of $37.90 billion, a price-to-earnings ratio of 27.54, a price-to-earnings-growth ratio of 1.89 and a beta of 0.66.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 48.20% and a net margin of 8.16%.Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.